SAMe for depression
This article was originally published in The Tan Sheet
Executive Summary
Augmentation of antidepressant therapy with S-adenosyl-L-methionine (SAMe) "warrants a placebo-controlled trial in resistant depression," authors of a Pharmavite-sponsored trial conclude in the Dec. 6 Journal of Clinical Psychopharmacology. Jonathan Alpert, MD/PhD, Massachusetts General Hospital, et al., administered 800 to 1,600 mg of SAMe to antidepressant partial and non-responders over a six-week period, recording a 50% response rate and a 43% rate of remission. A double-blind, placebo-controlled study at NIH to test SAMe as an adjunct antidepressant therapy also is being conducted by Alpert et al. A second NIH study will test SAMe against standard antidepressants and placebo...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.